

Immunology and Immunochemistry (Virtual)

October 26, 2020

Session:	Immunotherapy in Cancer
Chair:	Eduardo Davila , University of Colorado CU Comprehensive Cancer Center, CO
09:45-10:15	Oncolytic Reagents may also Enhance Anti-Tumor Immunity by Inducing MyD88-dependent Maturation of Dendritic Cells Joost J. Oppenheim , NIH/NCI, MD
10:15-10:45	Overcoming a Frequent Inborn Immune Defect in Breast Cancer Therapy Guido Kroemer , Gustave Roussy Comprehensive Cancer Center, INSERM, France
10:45-11:00	Break
11:00-11:30	Versamune (R-D0TAP): a Transformative Cationic Lipid Nanoparticle Technology Associated with Type I Interferon Specific Activation and Generation of Antibody, CD8 and CD4 T Cell Responses to Recombinant Proteins and Peptide Tumor Antigens Lauren V. Wood , Chief Medical Officer, PDS Biotechnology, NJ
11:30-11:55	Tumor-Derived Exosomes and Their Role in Cancer Progression Theresa L. Whiteside , University of Pittsburgh School of Medicine and UPMC Hillman Cancer Center, PA
11:55-12:20	Title to be updated Scott K. Durum , NCI/CCR, NIH, MD
12:20-12:45	Novel Gene Platforms to Maintain the Persistence and Antitumor Activity of TIL-, CAR-, and DC-Based Therapies Eduardo Davila , University of Colorado CU Comprehensive Cancer Center, CO
12:45-13:10	Lunch
13:10-13:35	UNITE Platform, A Direct Antigen Presentation Approach in Oncology William Hearl , Ph.D. CEO, Immunomic Therapeutics, MD
13:35-14:00	Dual Antagonism of Prostaglandin Receptors EP2 and EP4 by TPST-1495 Suppresses Tumor Growth and Stimulates Antitumor Immunity Brian Francica , Tempest Therapeutics, CA
14:00-14:25	MHC Class-I Independent Activation of Virtual-Memory CD8 T Cells Induced by Chemotherapeutic Agent-Treated Cancer Cells Jing H. Wang , University of Colorado Anschutz Medical Campus, CO
14:25-14:50	SA-4-1BBL, a novel immune checkpoint agonist, invokes an innate immune surveillance mechanism with long-term protective efficacy against various tumor types Haval Shirwan , FasCure Therapeutics, LLC, Louisville, KY
14:50-15:00	Break
15:00-15:25	The MAPK/ERK-regulated MEF-2 isoforms as potential new target(s) for HTLV-1 induced Adult T-cell leukemia/lymphoma (ATLL) Pooja Jain , Drexel University College of Medicine, Philadelphia, PA
15:25-15:50	Performance Optimization of a Novel HPV VLP Vaccine in Mice with Novel Adjuvants Jason D. Marshall , Leidos Biomedical Research, Inc., NCI Campus at Frederick, MD
15:50-16:15	Duality of NO in Melanoma Joseph Markowitz , Moffit Cancer Center, FL
16:15-16:40	Metabolic Requirements for T Cell Protein Translation in Tumors Jessica E. Thaxton , Medical University of South Carolina, SC
16:40-17:05	Finetune Your CARs: Building the Next Generation of Anti-Cancer Therapies Yan Leyfman , Penn State College of Medicine, PA
	E-posters
Poster-01	«Carplasmin» - The New CEA-specific Plasmid-based CAR Demonstrating a High Potential in an in-vivo Xenograft Mouse Model Yana Kiseleva , Russian Scientific Center of Roentgenoradiology, Russia